Press Releases
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
